Ram I. Mahato, Ph.D.

Professor (Tenured)

Office location

Cancer Research Building
19 South Manassas (Room 224)
Memphis, TN 38103-3308
Tel: (901) 448-6929
Tel(lab): (901)448-6848
Fax: (901) 448-2099
Email: rmahato@uthsc.edu

Current Office Hours

by appointment

Lab Links

Ram I. Mahato, Ph.D.

Research Activities and Interests

Our laboratory in the College of Pharmacy (see video for details) has expertise in molecular and cell biology, biochemistry, biophysics, polymer chemistry, colloid science, pharmaceutics, and medicine. This allows us to take a multidisciplinary approach for successful research and training students and post-doctoral fellows. Our research is focused on the following areas: (i) Micelle and Nanoparticulate Drug Delivery, (ii) Oligonucleotides, siRNA, shRNA and Gene Delivery (iii) Synthesis of Novel Polymers, Lipopeptides, Lipopolymers and Cationic Lipids (iv) Construction of Plasmid and Adenovirus-based Gene and shRNA Expression Systems. These systems are being tested in various disease areas such as improving islet transplantation to treat type 1 diabetes, cancer (pancreatic, prostate and breast) and liver fibrosis.

We attempt to understand how the individual components of delivery and expression systems would influence the disease state by controlling gene regulation, transcription, translation and replication. In addition to using stem cells as gene delivery vehicle for inducing immune tolerance in diabetes and fibrosis, we are also working to overcome multi drug resistance in tumors by targeting cancer stem cells.

Curriculum Vitae

Degree

  • Ph.D. in Pharmaceutics and Drug Delivery from the University of Strathclyde Britain(1989-92)
  • B.S. in Pharmaceutics from China Pharmaceutical University, China (1985-89).
  • Diploma in Chinese from Beijing Language Institute, China (1984-1985)
  • Certificate Level in Science from Tribhuwan University, Nepal (1981-83)

Professional Experience

Professor (2009-present), Associate Professor(2005-2009), Assistant Professor (2001-2005), Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Research Assistant Professor, Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah (1999-2001), Senior Scientist, Gene Delivery Sciences, GeneMedicine, inc. (Valentis, Inc., 1996-99), Research Scholar, Gene Delivery Sciences, Faculty of Pharmaceutical Sciences, Kyoto University, Japan (1994-96), Postdoctoral Fellow, Departments of Chemical Engineering and Ophthalmology, Washington University, St. Louis (1993-1994), Research Associate, Department of Pharmaceutical Sciences, University of Southern California, Los Angeles (1992).

Honors and Awards

  • 2011 Fellow, Controlled Release Society (CRS)
  • 2010 Fellow, American Association of Pharmaceutical Scientists (AAPS)
  • 2010 Visiting Professor, Institute for Integrated Cell Material Sciences, Kyoto University, Japan
  • 2009 Permanent Member of the BTSS study section of the NIH from July 2009-June 2013
  • 2009 Outstanding Teaching Awards, College of Graduate Health Sciences, Univ. of Tennessee
  • 2009 Invited to Diabetes and Obesity Global Therapeutic Expert Forum, Merck & Co., May 2-3, 2009, New York
  • 2006 Nonviral Gene Transfer Vectors Scientific Committee Member, American Society of Gene Therapy; Symposium Chair, Biomaterials for Site-specific Delivery of Oligonucleotides and siRNA, National Biotechnology Conferences (June 18-21, Boston, MA)
  • 2005 Short Course Chair, Pharmaceutical Perspectives of Synthetic and Hybrid Vectors-based Nucleic Acid Therapeutics, 2005 AAPS Annual Meeting and Exposition (Nashville, 2005)
  • 2004 Invited Speaker, Modulation of Gene Expression by Antisense, Antigene and sRNAi, 31st Controlled Release Society (CRS) Annual Meeting (Hawai, 2004); Invited Speaker, Viral Medicine? Never, Pearls of Wisdom, 31st Controlled Release Society (CRS) Annual Meeting (Hawai, 2004)
  • 2003 Invited Speaker, Challenges of Antisense Oligonucleotide Delivery, 30th Controlled Release Society (CRS) Annual Meeting (Glasgow, UK, 2003); Who’sWho in America (2003)
  • 2002: Invited Speaker on Functional and Biospecific Polymers for Therapeutic Gene Delivery, AAPS Workshop on Critical Issues in the Design & Applications of Polymeric Biomaterials in Drug Delivery (Arlington, VA, 2002)
    Session Chair, Therapeutic Gene/Oligonucleotide Delivery, 29th CRS Annual Meeting (Seoul, Korea, 2002)
  • 2000 Invited Speaker on Introduction to Gene Therapy at Sunrise School of Pharmacy at the AAPS Annual Meeting (Indianapolis, 2000)
  • 1999 Invited Speaker, Tailor made polymeric gene carriers at the 3rd Congress of Eur Assoc Clin Pharmacol Ther (EACPT) (Jerusalem, Israel, 1999)
  • 1995-96 Goho Foundation Fellowship (Japan)
  • 1994-95 Uehara Foundations Fellowship (Japan)
  • 1989-92 Cancer Research Campaign PhD Studentship of the United Kingdom
  • 1986 International Student Award by China Pharmaceutical University, China
  • 1984-8 Undergraduate studies supported by the Ministry of Education, Nepal

Scientific Review Panels

  1. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, February 7-8, May 21-22 & Oct 11-12, 2012
  2. Pennsylvania Final Review Performance Review, 12-13 Cycle A, Oak Ridge Associated Universities, 2012
  3. 2011 PCRP Clinical & Experimental Therapeutics #2 Panel Meeting, Department of Defense, October 12-14, 2011.
  4. Pennsylvania Final Review Performance Review, 11-12 Cycle A, Oak Ridge Associated Universities, 2011.
  5. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, February 6-8, May 16-17 & Oct, 2011.
  6. 2010 Prostate Cancer Research Program - PRE-CET-D, April 2010.
  7. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, Feb 11-12, May 17-18 & Oct 11-12, 2010.
  8. Pennsylvania Final Review Performance Review, 10-11 Cycle A, Oak Ridge Associated Universities, 2010.
  9. Susan G. Komen for the Cure: Localized Chemotherapies, 2010.
  10. Estonian Science Foundation, September 2009.
  11. Nangyang Technological University, Singapore, August 2009.
  12. PCRP Clinical & Experimental Therapeutics #1 Panel Meeting, Department of Defense, July 26-28, 2009.
  13. 2009/10 ZRG1 SBIB-V (58) RFA OD-09-003 NIH Challenge Panel#23 and BST-M (58) RFA OD-09-003 Challenge Grants Panel 4.
  14. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, May 18-19 & October 6-7, 2009.
  15. World Class University (WCU) International Review Panel, WCU-KOSEF, Washington, DC., April 5-6, 2009.
  16. 2009 Prostate Cancer Research Program - PRE-CET-B, April 2009.
  17. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, February 8-9, 2009.
  18. Susan G. Komen for the Cure: Localized Chemotherapies, 2009.
  19. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, October 6-7, 2008.
  20. Clinical &Experimental Therapeutics-3 (CET-3) Panel Meeting, Department of Defense, July 20-22, 2008.
  21. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, May 19-20, 2008.
  22. National Institutes of Health, Bioengineering, Technology and Surgical Sciences (BTSS) Study Section, February 4-5, 2008.
  23. Susan G. Komen for the Cure Panel Meeting at Alexandria, VA, January 10-11, 2008.
  24. National Institutes of Health, Special Emphasis Panel on Enzyme Assessment Core, NIDDK, November 15, 2007.
  25. Clinical & Experimental Therapeutics-3 (CET-3) Panel Meeting, Department of Defense, August 15-17, 2007.
  26. Israel Science Foundation, March 2007.
  27. Wellcome Trust, Great Britain, January 2007.
  28. Alberta Heritage Foundation for Medical Research, Canada, December 2006.
  29. National Institutes of Health, Nanoscience and Nanotechnology, Washington D.C., July 2004.
  30. National Institutes of Health, Nanoscience and Nanotechnology (Washington D.C., March 2004.
  31. James and Esther King Biomedical Research Program, 2004-Present.
  32. Engineering & Biological Systems (EBS) of Great Britain, April, 2004.
  33. American Institute of Biological Sciences, October-November, 2002.
  34. National Institutes of Health, Gene Therapy Panel, March, 2002.

Service to Professional Associations

Moderator

  1. SPIE: Nanosystems in Engineering and Medicines, Incheon, Korea, Sep 10-12, 2012.
  2. 15th International Biotechnology Symposium & Exhibition (IBS), Daegu, Korea, Sep 16-21, 2012
  3. Bioactive Materials: Regenerative Medicines, 32nd 38th Annual Meeting & Exposition of the Controlled Release Society, Washington DC, August 2, 2011.
  4. Plus/Minus Complexes, 15th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, UT, February 13-16, 2010.
  5. Site-specific Delivery and Targeting of Nucleic Acids for treating Fibrosis, 2008 National Biotechnology Conference (NBC), Toronto, Canada, June, 2008.
  6. Nanoencapsulation I, 34th Controlled Release Society Annual Meeting, Long Beach, CA, July, 2007.
  7. Session 13: Solutions to Novel Drug Delivery System, 5th Annual Drug Discovery Conference and Expo (IDDST), Shanghai, China, May 27-31, 2007.
  8. Biomaterials for Site-specific Delivery of Oligonucleotides and siRNA; and Emerging Trends in Cell-Based Therapeutics, National Biotechnology Conferences, Boston, MA, June 18-21, 2006.
  9. Delivery, Transport and Transcription, 9th Annual Meeting of American Society of Gene Therapy (ASGT), Baltimore, MD, May 31-June 4, 2006.
  10. Short Course Chair on Pharmaceutical Perspectives of Synthetic and Hybrid Vectors-based Nucleic Acid Therapeutics, AAPS Annual Meeting and Exposition, Nashville, October, 2005.
  11. Delivery of Nucleotide-based Therapeutics, 32nd Controlled Release Society Annual Meeting (Miami, Florida, 2005).
  12. Workshop Chair on Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics, 31st Controlled Release Society (CRS) Annual Meeting, Hawaii, July, 2004.
  13. Challenges for Oligonucleotide Delivery, 30th Controlled Release Society Annual Meeting (Glasgow, Scotland, 2003)
  14. Therapeutic Gene/Oligonucleotide Delivery, 29th CRS Annual Meeting, Seoul, Korea, July, 2002.

Symposia/Workshop Organizer

  1. Workshop on siRNA Delivery at SMi Group’s 6th Conference on Controlled Release, London, UK, March 11-12, 2009 (Role: Organizer).
  2. CRS 2008 Educational Workshop Review Committee, 35th Controlled Release Society Annual Meeting, New York, NY (Role: Member).
  3. Workshop Chair on Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics, 31st Controlled Release Society (CRS) Annual Meeting, Hawaii, July, 2004 (Role: Organizer).
  4. Round-table on Disposition of Nonviral Gene Delivery Systems and Oligonucleotides. Annual AAPS Meeting, San Francisco, CA, November, 1998 (Role: Co-organizer along with Shankar Musunuri and Uday B. Kompella).
  5. Member, 2007 CRS/Jorge Heller Journal of Controlled Release Award Committee.

Editorial Activities

Editor:

Editorial Board:

Research Support

Active:

2R01 DK069968-06 7/1/09-6/30/13

  • Principal Investigator: Ram I. Mahato, Ph.D. (40%)
  • Growth Factor and Antiapoptotic Gene Delivery to Human Islets
    The goal of this competing renewal of R01 DK069968 is to develop adenovirus-based growth factor and antiapoptotic gene delivery to human pancreatic islets for treatment of type I diabetes. This proposal has received 15.4% and a priority score of 156. This is most likely to be funded.
    Total Direct: $1,125,000

W91ZSQ0209N6010001 09/20/10-9/19/13

  • Principal Investigator: Ram I. Mahato, Ph.D.
  • Micellar Drug Delivery and Proteomics Analysis for Effective Treatment of Resistant Prostate Cancer.
    The goal of this project is to develop micellar drug delivery systems using novel polymers for effective treatment of resistant prostate cancer.
    Total Direct: $ 450,000

Discovery of Novel Thiazole Analogs for Treating Malignant Melanoma

  • Principal Investigator: Wei Li, Co-I: Ram I. Mahato 0.96 calendar months
  • Agency: NIH
  • Period: 01/01/11-12/31/15 R01 CA148706-01
    Total Direct: $1,250,000
    The goal of this project is to develop novel thiazole analogs which can be used to treat melanoma and enhance their delivery to melanoma tumors using polymeric nanoparticles.

Combination Therapy with EGFR and Hedgehog Inhibitors for Treating Pancreatic Cancer

  • Principal Investigator: Ram I. Mahato
  • Agency: Kosten Foundation
  • Period: 09/01/11-08/31/12
    Total Direct: $67,858
    The goal of this project is to develop combination therapy to simultaneously target cancer stem cells and bulk cancer cells to advanced pancreatic cancer.

Completed:

NIH/R01 EB003922-05 03/1/07– 11/30/10

  • Principal Investigator: Ram I. Mahato, Ph.D. (25%)
  • Targeted Delivery of TFOs for Treatment of Liver Fibrosis
    The major goal of this project is to targeted delivery of a1(I) collagen gene promoter specific triplex forming oligonucleotides (TFOs) to liver fibrogenic cells in fibrotic rats after conjugation with mannose 6-phosphate-bovine serum albumin (M6P-BSA) via a disulfide bond.
    Total Direct: $667,520

NIH/R01 DK069968-01A1 8/1/05-7/31/13

  • Principal Investigator: Ram I. Mahato, Ph.D. (40%)
  • Growth Factor and Antiapoptotic Gene Delivery to Human Islets
    The goal of this project is to develop adenovirus-based growth factor and antiapoptotic gene delivery to human pancreatic islets for treatment of type I diabetes.
    Total Direct: $784,000

NIH/R01 DK64366-01A1 01/01/04-12/31/08

  • Principal Investigator: Ramareddy V. Guntaka, Ph.D.
  • Coinvestigator: Ram I. Mahato, Ph.D. (13.5%)
  • A Promoter-Specific TFO Prevents Liver Fibrosis
    Fibrosis is due to abnormal accumulation of type I collagen in the interstitial space of various organs. The goal of this project is to use a triplex-forming oligonucleotide as an antigene agent targeting the promoter of ?1(I) collagen gene.
    Total Direct: $1,445,400

UT Rheumatic Diseases Research Core Center Grant 9/01/04-9/30/06

  • Principal Investigator: Ram I. Mahato, Ph.D.
  • Targeted Delivery of Oligonucleotides into Hepatic Stellate Cells
    Total Direct: $40,000
    The goal of this project is to develop receptor-mediated delivery strategies for oligonucleotides to hepatic stellate cells to inhibit collagen production for treatment of liver fibrosis.
    UT Vascular Biology Center of Excellence provided $18,000 in 2003 and $10,000 in 2004 to support one graduate student.

Project Title: Development of Water Soluble Lipopolymers for Gene Delivery

  • Funding Agency: Expression Genetics, Inc.
  • Funding Period: 5/1/02-5/31/03
    Total Direct: $30,000
    Role: PI

Project Title: Development of Novel Gene Delivery Systems

  • Funding Agency: UT New Faculty Start-up Fund: $250,000
  • Funding Period: 5/1/02-5/31/03
    Total Direct: $250,000
    Role: PI

Project Title: Enhancement of Human Islet Engraftment by Gene Therapy. USPHS/NIH DK57700

  • Total Direct: $1,250,000
    Current Year Direct: $214,500
    Your Role: Collaborator (PI: A. Osama Gaber, M.D.)

Teaching and Faculty Responsibilities

  • PHSC111: Physical Pharmacy to PharmD Students.
  • PHSC911: Delivery and Biocompatibility of Protein and Nucleic Drugs to Graduate Students.
  • Director, Graduate Seminar Programs and courses (PHAC 819, PHAC 919, MEDC 819, and MEDC 919), UTHSC.
  • Member, Graduate Curriculum and Faculty Development Committees, University of Tennessee Health Science Center, Memphis, TN.

Selected Publications

Book editor

  1. Mahato RI and Narang AS Pharmaceutical Dosage Forms and Drug Delivery, 2nd Edition (2011), CRC Press, Inc., FL
  2. Narang AS and Mahato RI (Eds) Targeted Delivery of Small and Macromolecular Drugs (2010), CRC Press, Inc., FL
  3. Lu Y and Mahato RI (Eds) Pharmaceutical Perspectives of Cancer Therapeutics (2009), Springer/AAPS Publication
  4. Mahato RI. Pharmaceutical Dosage Forms and Drug Delivery(2007), CRC Press, Inc., FL
  5. Mahato RI (Ed) Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids(2005), CRC Press, Inc., FL
  6. Mahato RI and Kim SW (Eds) Pharmaceutical Perspectives of Nucleic Acid-Based Therapeutics (July 2002), Francis and Taylor, London.

Journal Theme Issue Editor

  1. Cheng K and Mahato RI (2011) Biological and Therapeutic Applications of Small RNAs. Pharm. Res. 28: 2961-2965.
  2. Ye Z and Mahato RI (2011) Emerging Trends in Gene- and Stem Cell-based Combination Therapy. Mol. Pharmaceutics 8: 1443-1445.
  3. Zhang XA and Mahato RI (2011) Target cell movement in cardiovascular and malignant diseases. Adv Drug Del Rev 63: 555-557
  4. Wang DA and Mahato RI (2010) Therapeutic cell delivery for in situ regenerative medicine. Adv Drug Del Rev 62: 669-70.
  5. Cheng K and Mahato RI (Eds) Special Issue on siRNA Delivery (2009) Mol. Pharm. 6: 649-50.
  6. Lee M and Mahato RI (Eds) Special Issue on the Gene Regulation for Effective Gene Therapy (2009) Adv. Drug Del. Rev.61: 487-488.
  7. Ye Z and Mahato RI (Eds) Special Issue on the Emerging Trends in Cell-based Therapeutics (2008) Adv Drug Del Rev 60: 89-90
  8. Mahato RI (Ed) Special Issues on Gene Delivery and Targeting (1999 and 2000) Journal of Drug Targeting7: 241-313; 7: 407-470; and 8:1-66.
  9. Mahato RI (Ed) Theme Issue on Challenges of Turning Nucleic Acids into Therapeutics (2000) Adv. Drug Del. Rev. 44 (2-3): 79-207.

Editorials & Commentaries

  1. Danquah N, Singh S, Behrman S and Mahato RI (2012) Danquah N, Singh S, Behrman S and Mahato RI (2012) Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. Expert Opin. Drug Deliv. [Early Online]
  2. Cheng K and Mahato RI (2009) siRNA Delivery and Targeting. Mol Pharm 6: 649-50.
  3. Lee M and Mahato RI (2009) Gene Regulation for Effective Gene Therapy. Adv. Drug Del. Rev.61:487-488.
  4. Ye Z and Mahato RI (2008) Role of nanomedicines in cell-based therapeutics. Nanomedicines 3: 5-8. .
  5. Mahato RI and Narang AS (2005) Need of closer alliances for turning nucleic acids into nanomedicines. CRS Newsletter 22(1): 22, 25, 31.
  6. Book Review: A. Rolland and S.M. Sullivan, Editors, Pharmaceutical Gene Delivery Systems, Marcel Dekker, New York (2004) (424 pp.), J Control Rel 104: 233-234.
  7. Mahato RI (2000) Challenges of turning nucleic acids into therapeutics. Adv Drug Deliv Rev 44: 79-80.
  8. Mahato RI (1999): Editorial: Plasmid-based gene therapy: Opportunities and challenges knock the millennium. J Drug Target 7: 241-244.
  9. Mahato RI, Fons MP and A Rolland (1998) Nonviral gene therapy: From Bench to the Clinic. CRS Newsletter 15: 9-11 .

Patents & Invention Disclosures

  1. RI Mahato, AO Gaber, AS Narang, D Fraga and M Kotb (2003) Vascular endothelial growth factor gene delivery to human islets for neoangiogenesis after transplantation. Filed for patent by the University of Tennessee Health Science Center, Memphis.
  2. RI Mahato, A Maheshwari and SW Kim (2005) Soluble steroidal peptides for nucleic acid delivery. US Patent# 6,875,611 and  7,320,890 B2
  3. RI Mahato, SO Han and DY Furgeson (2004) Cationic lipopolymer as biocompatible gene delivery agent. US Patent# 6,696,038.

Research Papers

  1. Michael Danquah M, Fujiwara T and Mahato RI (2012) Lactic acid- and carbonate-based crosslinked polymeric micelles for drug delivery. J Polymer Sci: Polymer Chem (ePublication)
  2. Mundra V, Danquah M, Li W, Miller DD and Mahato RI (2012) Formulation and characterization of polyester/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent. Pharm Res 29: 3064-74.
  3. Pratap A, Singh S, Mundra V, Yang N, Panakanti R, Eason1 JD and Mahato RI (2012) of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. J Drug Target (early online).
  4. Danquah M, Duke III CB, Patil R, Miller DD and Mahato RI (2012) Combination Therapy of Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer. Pharm Res 29: 2079–2091.
  5. Singh S, Chitkara D, Mehrazin R, Behrman SW, Robert W. Wake RW and Mahato RI (2012) Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway. PLoS ONE 7(6): e40021.
  6. Wu H, Yoon AR, Li F, Yun CO and Mahato RI (2011) RGD peptide-modified adenovirus expressing hepatocyte growth factor and X-linked inhibitor of apoptosis improves islet transplantation. J. Gene Med. 13: 658–669.
  7. Li F, Danquah Mm, Singh S, Wu H and Mahato RI (2011) Paclitaxel- and lapatinib-loaded lipopolymer micellesovercome multidrug resistance in prostate cancer. Drug Deliv. Transl. Res. 1: 420–428
  8. Pratap A, Panakanti R, Yang N, Lakshmi R, Modanlou KA, Eason JD and Mahato RI (2011) Cyclopamine attenuates acute warm ischemia reperfusion injury in cholestatic rat liver: Hope for marginal livers. Mol Pharm 8: 958–968.
  9. Wu H, Lu W and Mahato RI (2011) Mesenchymal Stem Cells as a Gene Delivery Vehicle for Successful Islet Transplantation. Pharm Res (ePublication, April 16)
  10. Lu W, Li F and Mahato RI (2011) Poly(ethylene glycol)-Block-Poly(2-methyl-2-benzoxycarbonylpropylene Carbonate) Micelles for Rapamycin Delivery: In Vitro Characterization and Biodistribution. J Pharm Sci 100: 2418-2429.
  11. Yang N and Mahato RI (2011) GFAP Promoter-Driven RNA Interference on TGF-ß1 to Treat Liver Fibrosis. Pharm Res. 28: 752-61.
  12. Zhu L, Mahato RI (2010) Targeted Delivery of siRNA to Hepatocytes and Hepatic Stellate Cells by Bioconjugation. Bioconjug Chem. 21: 2119-2127.
  13. Panakanti R, Pratap A, Yang N, Jackson JS and Mahato RI (2010) Triplex forming oligonucleotides against type a1(I) collagen attenuates liver fibrosis induced by bile duct ligation. Biochem Pharmacol (ePublication)
  14. Li F, Danquah M and Mahato RI (2010) Synthesis and Characterization of Amphiphilic Lipopolymers for Micellar Drug Delivery. Biomacromolecules (ePublication)
  15. Pratap A, Panakanti R, Yang N, Eason JD and Mahato RI Inhibition of Endogenous Hedgehog Signaling Protects against Acute Liver Injury after Ischemia Reperfusion. Pharm Res (ePublication)
  16. Wu H, Panakanti R, Li F, Mahato RI (2010) XIAP Gene Expression Protects beta-Cells and Human Islets from Apoptotic Cell Death. Mol Pharm. 2010 Aug 2. [Epub ahead of print]
  17. Li F, Lu Y, Li W, Miller DD, Mahato RI (2010) Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100. J. Control Release 143: 151–158.
  18. Danquah M, Fujiwara T, Mahato RI (2010) Self-assembling methoxypoly (ethylene glycol)-b-poly(carbonate-co-l-lactide) block copolymers for drug delivery. Biomaterials. 31: 2358–2370.
  19. Danquah M, Li F, Duke III C, Miller DD and Mahato RI (2009) Micellar Delivery of Bicalutamide and Embelin for Treating Prostate Cancer. Pharm Res 26: 2081-92.
  20. Li F and Mahato RI (2009) Bipartite Vectors for co-expression of a Growth Factor cDNA and shRNA against an Apoptotic Gene. J Gene Med 11: 764-771.
  21. Cheng K, Yang N and Mahato RI (2009) TGF-ß1 Gene Silencing for Treating Liver Fibrosis. Mol Pharm 6: 772-9.
  22. Yang N, Ye Z, Li F and Mahato RI (2009) HPMA Polymer-based Site-specific Delivery of Oligonucleotides to Hepatic Stellate Cells. Bioconjugate Chem 20:213-221.
  23. Panakanti R and Mahato RI (2009) Bipartite Adenoviral Vector encoding hVEGF and hIL-1Ra for Improved Human Islet Transplantation. Mol Pharm6: 274-284.
  24. Zhu L, Lu Y, Miller DD and Mahato RI (2008) Structural and Formulation Factors Influencing Pyridinium Lipid-based Gene Transfer. Bioconjugate Chem 19: 2499-2512.
  25. Panakanti R and Mahato RI (2009) Bipartite Adenoviral Vector encoding hHGF and hIL-1Ra for Improved Human Islet Transplantation. Pharm Res 26: 587-596.
  26. Cheng G, Zhu L and Mahato RI (2008) Caspase-3 Gene Silencing for inhibiting Apoptosis in Insulinoma Cells and Human Islets. Mol Pharm 5:1093-1102.
  27. Li F and Mahato RI (2008) iNOS gene silencing prevents inflammtory cytokine induced beta cell apoptosis. Mol Pharm 5: 407-417.
  28. Chen Y and Mahato RI (2008) siRNA Pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. J Drug Target 16:140-148.
  29. Zhu L, Ye Z, Cheng K, Miller DD and Mahato RI (2008) Site-specific delivery of oligonucleotides to hepatocytes after systemic administration. Bioconjugate Chem 19: 290-8.
  30. Ye Z, Guntaka RV and Mahato RI (2007) Sequence-specific triple helix formation with genomic DNA. Biochemistry 46: 11240-11252.
  31. De Paula D, Bentley MV and Mahato RI (2007) Effect of iNOS and NF-kB gene silencing on ß-cell survival and function. J Drug Target 15:358-369.
  32. Jia X, Cheng K and Mahato RI (2007) Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist for improved human islet survival and function.Molecular Pharmaceutics 4:199-207.
  33. Narang AS, Sabek O, Gaber AO, and Mahato RI (2006) Co-expression of vascular endothelial growth factor and interleukin-1 receptor antagonist improves human islet survival and function. Pharm Res23: 1970-1982.
  34. Ye Z, Cheng K, Guntaka RV and Mahato RI (2006) Receptor-mediated Hepatic Uptake of M6P-BSA-conjugated Triplex Forming Oligonucleotides in Rats. Bioconjugate Chem 17:823-830.
  35. Cheng K, Ye Z, Guntaka RV and Mahato RI (2006) Enhanced hepatic uptake and bioactivity of type a1(I) collagen gene promoter specific triplex forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther 317: 797-805
  36. Cheng K, Ye Z, Guntaka RV and Mahato RI (2005) Biodistribution and Hepatic Uptake of Triplex Forming Oligonucleotides Against Type ?1(I) Collagen Gene Promoter in Normal and Fibrotic Rats. Molecular Pharmaceutics 2: 206-217.
  37. Ye Z, Cheng K, Guntaka RV and Mahato RI (2005) Targeted delivery of triplex forming oligonucleotides to hepatic stellate cells. Biochemistry 44: 4466-4476.
  38. Narang AS, Thoma L, Miller DD, Mahato RI (2005) Cationic lipids with increased DNA binding affinity for nonviral gene transfer in dividing and nondividing cells. Bioconjug Chem 16:156-168.
  39. Cheng K, Fraga D, Kotb M, Gaber AO, Guntaka RV and Mahato RI (2004) Adenovirus-based vascular endothelial growth factor gene delivery to human islets. Gene Ther 11: 1105-1116.
  40. Narang AS, Cheng K, Henry J, Zhang C, Sabek O, Fraga D, Kotb M, Gaber AO and Mahato RI (2004) Vascular endothelial growth factor gene delivery to human islets for neoangiogenesis after transplantation. Pharm Res.21:15-25.
  41. Mahato RI, Henry J, Narang AS, Sabek O, Fraga D, Kotb and Gaber AO (2003) Cationic lipid and polymer-based gene delivery to human pancreatic islets. Mol. Ther. 7: 89-100.
  42. Wang D-A, Narang AS, Kotb M, Gaber OA, Miller DD, Kim SW and Mahato RI (2002) Novel branched poly(ethylenimine)-cholesterol water soluble lipopolymers for gene delivery. Biomacromolecules 3: 1197-1207.
  43. Maheshwari A, Mahato RI and Kim SW (2002) Biodegradable polymer-based interleukin-12 gene delivery: Role of induced cytokines, tumor infiltrating cells and nitric oxide in anti-tumor activity. Gene Ther 9:1075-1084.
  44. Furgeson DY, Cohen RN, Mahato RI and Kim SW (2002) Design, synthesis and characterization of novel lipoparticulates for systemic gene delivery. Pharm Res 19:382-390.
  45. Benns JM, Mahato RI and Kim SW (2002) Optimization factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylimine. J Control Release 79:255-269.
  46. Benns JM, Maheshwari A, Furgeson DY, Mahato RI and Kim SW (2001) Folate-PEG-Folate-graft-polyethylenimine-based gene delivery. J Drug Target. 9: 123-139.
  47. Mahato RI, Lee M, Han S-O, Maheshwari A and Kim SW (2001) Intratumoral delivery of p2CMVmIL-12 using water soluble lipopolymers. Mol Ther 4:130-138.
  48. Han S-O, Mahato RI and Kim SW (2001) Synthesis and characterization of water-soluble lipopolymer for gene delivery. Bioconjug Chem 12: 337-345.
  49. Maheshwari A, Mahato RI, McGregor J, Han S-O, Samlowski WE, Park J-S and Kim SW (2000) Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment. Mol Ther 2: 121-130.
  50. Benns JM, Choi J-S, Mahato RI, Park J-S and Kim SW (2000) pH sensitive cationic polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb shaped polymer. Bioconjug Chem 11: 637-645.
  51. Nomura T, Yamada T, Mahato RI, Watanabe Y, Takakura Y and Hashida M (1999) Gene expression and antitumor effects following direct interferon-g gene transfer with naked plasmid DNA and DC-Chol liposome complexes in mice. Gene Ther 6: 121-129.
  52. Mahato RI, Anwer K, Tagliaferri F, Meaney C, Leonard P, Chen W, French M, Wadhwa MS and Rolland A (1998) Biodistribution and gene expression of plasmid/lipid complexes after systemic administration in mice. Hum Gene Ther 9: 2083-2099.
  53. Takagi T, Hashiguchi M, Mahato RI, Tokuda H, Takakura Y and Hashida M (1998) Involvement of specific mechanism in plasmid DNA uptake by mouse peritoneal macrophages. Biochem. Biophys. Res. Commun. 245: 729-733.
  54. Mahato RI, Takemura S, Takakura Y and Hashida M (1997) Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine). Biochem Pharmacol 53: 887-895.
  55. Takakura Y, Mahato RI, Yoshida M, Kanamaru T and Hashida M (1996) Uptake characteristics of oligonucleotides in the isolated rat liver perfusion system. Antisense Res Develop 6: 177-183.
  56. Sawai K, Mahato RI, Oka Y, Takakura Y and Hashida M (1996) Disposition of oligonucleotides in the isolated perfused rat kidney: Involvement of scavenger receptors in their renal uptake. J Pharmaco. Exp Ther 279: 284-290.
  57. Hashida M, Mahato RI, Kawabata K, Sawai K, Nishikawa M and Takakura Y (1996) Pharmacokinetics of proteins, oligonucleotides, and genes. J Contr Rel 41: 91-97.
  58. Yoshida M, Mahato RI, Kawabata K, Takakura Y and Hashida M (1996) Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion systems. Pharm Res 13: 597-601.
  59. Mahato RI, Kawabata K, Nomura T, Takakura Y and Hashida M (1995) Physicochemical and pharmacokinetic characteristics of DNA/cationic liposomes complexes. J Pharm Sci 84: 1267-1271.
  60. Mahato RI, Kawabata K, Takakura Y and Hashida M (1995) In vivo disposition of plasmid DNA complexed with cationic liposomes. J Drug Target 3: 149.
  61. Mahato RI, Halbert GW, Willmott N and Vezin WR (1994) Micron-sized biodegradable microspheres: Characterization and preparative techniques. J N ep Pharm Assoc 18:1-16.

Book Chapters

  1. Narang AS and Mahato RI (2009) Therapeutic potential of targeted drug delivery. In: Narang AS and Mahato RI (eds) Targeted Delivery of Small and Macromolecular Drugs, CRC Press, Inc.
  2. Panakanti R and and Mahato RI (2009) Recent advances in gene expression and delivery systems. In: Narang AS and Mahato RI (eds) Targeted Delivery of Small and Macromolecular Drugs, CRC Press, Inc.
  3. Yang N and and Mahato RI (2009) Delivery and targeting of oligonucleotides and siRNA. In: Narang AS and Mahato RI (eds) Targeted Delivery of Small and Macromolecular Drugs, CRC Press, Inc.
  4. Narang AS and and Mahato RI (2009) Targeting Colon and Kidney: Pathophysiological Determinants of Design Strategy. In: Narang AS and Mahato RI (eds) Targeted Delivery of Small and Macromolecular Drugs, CRC Press, Inc.
  5. Cheng G, Danquah M and Mahato RI (2009)MicroRNAs as therapeutic targets for cancer. In: Lu Y and Mahato RI (eds) Pharmaceutical Perspectives of Cancer Therapeutics. Springer, New York, NY.
  6. Cheng K and Mahato RI (2006) Biopharmaceutical Challenges: Pulmonary Delivery of Proteins and Peptides. In: Meibohm B (ed) Pharmacokinetics and Pharmacodynamics of Biotech Drugs, Wiley-VCH Verlag GmbH & Co,Weinheim, p. 209-242.
  7. Mahato RI, Ye Z and Kim WS (2006) Water soluble lipopolymers and lipopeptides for nucleic acid delivery. In: Friedmann T and Rossi J (eds) Gene Transfer: Delivery and expression of DNA and RNA, A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York, p. 501-506.
  8. Mahato RI and Kim SW (2005) Water soluble lipopolymers for gene delivery. In Amiji MM (ed) Polymeric Drug Delivery:Principles and Applications, CRC Press, Boca Raton, FL, p 175-186.
  9. Mahato RI, Ye Z and Guntaka RV (2005) Antisense and Antigene Oligonucleotides: Structure, Stability and Delivery. In Mahato RI (ed) Biomaterials for Delivery and Targeting of Protein and Nucleic acid Drugs, CRC Press, Boca Raton, FL.
  10. Mahato RI (2003) Pharmaceutical delivery systems and dosage forms. In Gourley D and Eoff J (eds) APhA’s Complete Review for Pharmacy, Castle Connolly Publishers, New York (2004).
  11. Mahato RI and Tomlison E (2001) Plasmid-based gene therapy. In: AM Hillery, AW Lloyd and J Swarbrick (eds) Drug Delivery and Targeting: For Pharmacists and Pharmaceutical Scientists, Taylor & Francis, London, pp. 372-397.
  12. Mahato RI, Furgeson DY, Maheshwari A, Han SO and Kim SW (2000) Polymeric gene delivery for cancer treatment. In:K.D. Park, I.C. Kwon, N. Yui, S.Y. Jeong and K. Park (eds) Biomaterials and Drug Deliver towards New Millennium, Han Rim Won Publishing Co., Seoul,Korea, pp. 249-280.
  13. Takakura Y, Mahato RI, Nomura T, Sawai K, Yoshida M, Kanamaru T and Hashida M (1995) ) Development of delivery systems for antisense oligonucleotides. In: Ogata N, Kim SW, Feijen J and Okano T (eds) Advanced Biomaterials in Biomedical Engineering and Drug Delivery Systems, Springer, New York, p. 357-358.

Review Articles

  1. Yang N, Singh S and Mahato RI (2011) Targeted TFO delivery to hepatic stellate cells. J Control Rel 155: 326–330
  2. Singh S, Narang AS and Mahato RI (2011) Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA. Pharm. Res. 28: 2996–3015.
  3. Wu H, Ye Z and Mahato RI (2011) Genetically Modified Mesenchymal Stem Cells for Improved Islet Transplantation. Mol. Pharmaceutics 8: 1458-1470.
  4. Danquah M, Zhang XA and Mahato RI (2011) Extravasation of polymeric nanomedicines across tumor vasculature. Adv. Drug Deliv. Rev. 63: 623-639.
  5. Li F and Mahato RI (2011) RNA interference for improving the outcome of islet transplantation. Adv. Drug Deliv. Rev. 63: 47–68.
  6. Zhu L and Mahato RI (2010) Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin. Drug Deliv. 7(10): 1-18.
  7. Kim HA, Mahato RI and Lee M (2009) Hypoxia-specific gene expression for ischemic disease gene therapy. Adv Drug Del Rev 61: 614-622.
  8. Mahato RI (2009) Expression and Silencing for Improved Islet Transplantation. J Control Release 140: 262–267.
  9. Chen Y, Cheng GF and Mahato RI (2008) RNAi for Treating Hepatitis B Viral Infection. Pharm Res 25: 72-86. .
  10. Ye Z, Houssein HSH and Mahato RI (2007) Bioconjugation of Oligonucleotides for Treating Liver Fibrosis . Oligonucleotides 17:349-404.
  11. Cheng K and Mahato RI (2007) Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst 24: 93-146.
  12. De Paula D, Bentley MV and Mahato RI (2007) Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA 13: 431-456.
  13. Narang AS and Mahato RI (2006) Biological and biomaterial approaches for improved islet transplantation. Pharmacol Rev 58: 194-243.
  14. Mahato RI (2005) Water insoluble and soluble lipids for gene delivery. Adv Drug Del Rev 57: 699-712.
  15. Mahato RI, Cheng K and Guntaka RV (2005) Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opinion on Drug Delivery 2:3-28.
  16. Mahato RI, Narang AS, Thoma L and Miller DD (2003) Emerging rends in oral delivery of peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 20: 153-214.
  17. Han S-O, Mahato RI, Sung YK and Kim SW (2000) Development of Biomaterials for Gene Therapy. Mol Ther 2: 302-317.
  18. Mahato RI (1999) Non-viral peptide-based approaches to gene delivery J. Drug Target. 7: 249-268.
  19. Mahato RI, Monera OD, Smith LC and Rolland A (1999) Peptide-based gene delivery. Cur Opin Mol Ther 2: 226-243.
  20. Mahato RI, Smith LC and Rolland A (1999) Pharmaceutical perspectives of nonviral gene therapy. Adv Genet 41: 95-156.
  21. Takakura Y, Mahato RI and Hashida M (1998) Extravasation of macromolecules. Adv Drug Del Rev 34: 93-108.
  22. Mahato RI, Rolland A and Tomlinson E (1997) Cationic lipid-based gene delivery systems: Pharmaceutical perspectives. Pharm Res 14:853-859.
  23. Mahato RI, Takakura Y and Hashida M (1997) Nonviral vectors for in vivo gene delivery: Physiochemical and pharmacokinetic considerations. Crit Rev Ther Drug Carrier Syst 14: 133-172.
  24. Mahato RI, Takakura Y and Hashida M (1997) Development of targeted delivery systems for nucleic acid drugs. J Drug Target 4: 337-357.
  25. Takakura Y, Mahato RI, Nishikawa M and Hashida M (1996) Control of pharmacokinetics of drugs using macromolecular carriers. Adv Drug Del Rev 19: 377-399.

Invited Speaker (National/International Meetings)

  1. Combination of Antiapoptotic drug and mesenchymal Stem Cells for Improving the Outcome of Islet Transplantation. NanoDDS’12, Atlantic City, New Jersey, October 29-30, 2012.
  2. Stem Cells and Gene Therapy for Improving Islet Transplantation. Department of Bioengineering, Hanyang University, Seoul, Korea, July 6, 2012.
  3. Delivery and Targeting of RNA Molecules for Treating Liver Diseases. 15th International Biotechnology Symposium and Exhibition, Daegu, Korea, September 16-21, 2012.
  4. Emerging Trends in RNA-based Combination Therapy. Global RNAi Carrier Initiative Symposium and Workshop, Korea Institute of Science & Technology (KIST), Seoul, Korea, July 4-6, 2012.
  5. Opportunities and Challenges in Turning RNAi Molecules into Therapeutics. 2012 Drug Delivery Symposium Honoring Prof. Vincent H.L. Lee, University of Colorado, Denver, June 14, 2012.
  6. Stem Cells and Gene Therapy for Improved Islet Transplantation. Endocrine Grand Round at the University of Tennessee Division of Endocrinology, Diabetes & Metabolism, May 3, 2012.
  7. Roles of Chemoresistance, Cancer Stem Cells and miRNA in treating Cancer using Polymeric Nanomedicines, Center for Drug Delivery and Nanomedicine, University of Nebraska Medical Center, April 19, 2012.
  8. Biodistribution and Cellular Uptake of Oligonucleotides for treating Liver Fibrosis, Bristol Myers Squibb, Princeton, NJ, April 12, 2012.
  9. Delivery and Targeting of siRNA and shRNA, Bristol Myers Squibb, Princeton, NJ, April 12, 2012.
  10. Roles of Chemoresistance, cancer stem cells and miRNA in Cancer Treatment. North Dokota State University, School of Pharmacy, Fargo, ND, Feb 23, 2012.
  11. Roles of Chemoresistance, Cancer Stem Cells and miRNA in treating Cancer using Polymeric Nanomedicines. University of Nebraska Center for Drug Delivery and Nanomedicine, April 19, 2012.
  12. Combination of Stem Cells and Gene Therapy for Improved Islet Transplantation. University of Colorado School of Pharmacy, Denver, CO, Sep 22, 2011.
  13. Bench to Business: Innovate or Perish. Departmental Seminar, University of Tennessee College of Pharmacy, Aug 29, 2011.
  14. Design Elements and Formulation Factors for Efficient Gene and siRNA Delivery. Workshop on Understanding the Organization of the Intracellular Region, University of Memphis, June 23-24, 2011.
  15. Polymeric Micelle-based Combination Therapy for Treating Advanced Prostate Cancer, University of Missouri Kansas City (UMKC) School of Pharmacy, Kansas City, MO, July 7, 2011.
  16. Site-Specific Delivery of Oligonucleotides and siRNA for Treating Liver Fibrosis, Nitto Denko Technological Corp, , Oceanside, CA, May 5, 2011.
  17. Polymeric Nanomedicines for treating Advanced Prostate Cancer. National Institute of Pharmaceutical Research (NIPER), Mohali, Punjab, India, March 21, 2011.
  18. Hedgehog Inhibitors Attenuate Ischemia Reperfusion Injury in Normal and Cholestatic Rat Livers. Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh, India, March 21, 2011.
  19. Polymeric Nanomedicines and Combination Therapy for treating Advanced Prostate Cancer. Center for Biomedical Engineering, National Institute of Technology (IIT), New Delhi, India, March 22, 2011.
  20. Mesenchymal Stem Cells as Gene Delivery Vehicles for Successful Islet Transplantation. Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), New Delhi, Inida, March 22, 2011.
  21. Bioconjugation for Site-Specific Delivery of Oligonucleotides and siRNA for Treating Liver Fibrosis, NIPER, Hydrabad, India, March 23, 2011.
  22. Mesenchymal Stem Cells as Gene Delivery Vehicles for Successful Islet Transplantation. Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), New Delhi, India, March 23, 2011.
  23. Delivery and targeting of Oligonucleotides and siRNA for treating Liver Diseases. International Conference on Biomaterials Science, March 15-18, 2011, Tsukuba, Japan.
  24. Mesenchymal Stem Cell-based Gene Therapy for improving the Outcome of Islet Transplantation. Division of Endocrinology Grand Rounds, University of Tennessee Health Science Center, August 12, 2010.
  25. Site-Specific Delivery and Targeting of Oligonucleotides and siRNA for treating liver diseases. International Forum on Liver Disease, Huai’An, China, June 11-13, 2010.
  26. Polymeric Nanomedicines for Treating Advanced Prostate Cancer, Institute of Biological Sciences and Biotechnology, Donghua University, Shanghai, China, June 9, 2010.
  27. Novel Amphiphilic Copolymers for Micellar Drug Delivery and Combination Therapy for Treating Prostate Cancer, East China University of Science and Technology, Shanghai, China, June 9, 2010.
  28. Gene Expression and Silencing for Improved Islet Transplantation, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, June 10, 2010.
  29. Polymeric Nanomedicines and Combination Therapy for the Treatment of Advanced Prostate Cancer, Biomedical Polymers for Drug Delivery 2010: In Honor of Prof Jindrich Kopecek’s 70th Birthday, March 26-27, 2010.
  30. Polymeric Nanomedicines and Combination Therapy for treating Resistant Prostate Cancer, Institute for Inovative NanoBio Drug Discovery and Development, Kyoto University, Japan, December 5, 2009.
  31. Polymeric Micelle-based Combination Therapy for Treating Advanced Prostate Cancer. California NanoSystems Institute, University of California, Los Angeles, November 12, 2009.
  32. Non-viral-based Gene Delivery: Obstacles, Challenges and O, Annual American Physical Society Meeting, Pittsburgh, PA, March 16-20, 2009.
  33. Gene Delivery and Silencing for Improved Human Islet Transplantation, SMi Group’s 6th Conference on Controlled Release, London, UK, March 11-12, 2009.
  34. Viral and Nonviral Gene Delivery, Department of Pharmacy Practice and Biopharmaceutical Sciences, University of Illinois at Chicago, January 21, 2008.
  35. Gene Expression and Silencing for Improved Islet Transplantation, 14th International Symposium on Recent Advances in Drug Delivery Systems, in Salt Lake City, UT, February, 2009.
  36. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Diseases, 2nd International Symposium for Intelligent Drug Delivery System, Seoul, Koreas, May 8-9, 2008.
  37. Targeted Delivery of Oligonucleotides and siRNA for Treating Liver Diseases, Singapore National University, May 6, 2008.
  38. Multiple Gene Silencing for Improved Islet Transplantation, Department of Materials Sciences, Seoul National University, Korea, May 7, 2008.
  39. Silencing of Multiple Antiapoptotic Genes for Improved Islet Transplantation, Nanyang University, Singapore, May 6, 2008.
  40. Gene Delivery and Silencing for treating Liver Diseases. School of Pharmacy, Chinese University of Hong Kong, May 5, 2008.
  41. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Diseases, School of Pharmacy, University of Minnesota, Minneapolis, March 27, 2008.
  42. Gene Expression and Silencing for Improved Human Islet Transplantation, School of Pharmacy, University of Kentucky, Lexington, KY, February 15, 2008.
  43. Gene Silencing for Improved Transplantation. Endocrinology Grand Round, University of Tennessee Health Science Center, Memphis, Jan 24, 2008.
  44. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Fibrosis and Hepatitis, School of Pharmacy, University of Manchester, United Kingdom, October 18, 2007.
  45. Site Specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Liver Diseases, Department of Pharmacy, Ludwig-Maximilians-Universität, Munich, Germany, October 16, 2007.
  46. Delivery and Targeting of Oligonucleotides and siRNA, Pfizer Global Research & Development, St Louis, MO, September 27, 2007.
  47. Site-specific Delivery of Oligonucleotides and siRNA, Department of Macromolecular Science, Fudan University, Shanghai, China, May 31, 2007.
  48. Site-specific Delivery and Targeting of Nucleic Acid Drugs for Treating Liver Diseases, China Pharmaceutical University, Nanjing, China, May 30, 2007.
  49. Site-specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Hepatitis and Liver Fibrosis, 5th Annual Drug Discovery Conference and Expo (IDDST), Shanghai, China, May 27-31, 2007.
  50. Site-specific Delivery of Nucleic Acids (ODNs and siRNA) for Treating Liver Fibrosis, University of London School of Pharmacy, April 26, 2007.
  51. ODN (antisense and antigene) and siRNA Delivery and Targeting, Industry and Health Authority Conference on: Oligonucleotide-based Therapeutics, Bethesda, MD, April 19-20, 2007.
  52. Site-specific Delivery of Oligonucleotides and siRNA for treating Liver Fibrosis, Endocrinology Grand Round, University of Tennessee Memphis, January 25, 2007.
  53. The Role of Scientific Journals on Our Travel to Gene and Nanoworld, Universidade de Sao Paulo, Brazil, August 29-31, 2006.
  54. Gene Therapy and Gene Silencing in Islet Transplant, Division of Endocrinology, University of Tennessee Memphis, August 22, 2006.
  55. Site-specific Delivery of Oligonucleotides and siRNA for Treatment of Liver Fibrosis, Faculty of Pharmaceutical Sciences, Utretch University, Netherlands, July 21, 2006.
  56. Site-specific Delivery of TFO and siRNA for Treatment of Liver Fibrosis, School of Pharmacy, University of Southern California, Los Angeles, CA, March 31, 2006.
  57. Gene Expression and Silencing for Improved Islet Transplantation, School of Pharmacy, University of Wisconsin, WI, September 16, 2005.
  58. Targeted Delivery of Triplex Forming Oligonucleotides to Hepatic Stellate Cells for Treatment of Liver Fibrosis, School of Pharmacy, University of Toronto, Canada, June 2005.
  59. Site-specific Delivery of Triplex Forming Oligonucleotides for Treatment of Liver Fibrosis. School of Pharmacy, University of Arkansas, Little Rock, AR, April 2005.
  60. A Travel to Gene and Nanoworld: A seminar to PharmD students, School of Pharmacy, University of Arkansas, Little Rock, AR, April 2005.
  61. Modulation of Gene Expression by Antisense, Antigene and sRNAi’ 31th Annual Meeting of the Controlled Release Society, Hawai, July 2004.
  62. Viral Vector never!! Pearls of Wisdom, 31th Annual Meeting of the Controlled Release Society, Hawai, July 2004.
  63. Viral and Non-viral Approaches to Human Islet Transplantation. Department of Allergy and Immunology, University of Tennessee, Memphis, December 8th, 2003.
  64. Triplex forming Oligonucleotide Delivery, Enzon, Inc. in Piscataway, NJ. (October 2, 2003).
  65. Challenges for oligonucleotide delivery. 30th Annual Meeting of the Controlled Release Society, Glasgow, Great Britain, July 2003.
  66. Vascular endothelial growth factor gene delivery to human islets for neoangiogenesis after transplantation, Department of Internal Medicinem Endocrinology and Diabetology, Universitat Sklinikum, Giessen, Germany, July 15, 2003
  67. Development of novel gene carriers and expression systems for the treatment of diabetes and cancer, Pharmaceutics and Biopharmacy at the Philipps-University, Marburg, Germany, July 16, 2003.
  68. Development of novel gene delivery systems for the treatment of diabetes and cancer, Department of Biopharmaceutics and Pharmaceutical Technology, University of Saarland, Saarbrucken, Germany, July 18, 2003.
  69. From bench to business: Tips for academics considering industrial careers, UT Graduate Research Student Day, May 2, 2003.
  70. Functional Polymer and Lipid-based gene delivery for treatment of cancer and diabetes, School of Biomedical Engineering, University of Tennessee Memphis, October 4, 2002.
  71. Development of gene delivery and expression systems for treatment of cancer and diabetes, Vascular Biology Center of Excellence, University of Tennessee Memphis, October, 2002.
  72. Gene delivery and expression systems for treatment of cancer and diabetes, Hepatitis C Group, University of Tennessee Memphis, September, 2002.
  73. Lipopolymeric Gene Delivery for the treatment of diabetes, Department of Materials Science, University of Tokyo, Japan, July 15, 2002.
  74. Nonviral Approaches for Gene Delivery to Human Islets, Division of Stem Cell Regulation Research, Osaka University, School of Medicine, Japan. July 17, 2002.
  75. Development of Synthetic Gene Carriers, Department of Chemistry, College of Natural Sciences, Seoul National University, South Korea. July 24, 2002.
  76. Polymeric Gene Delivery for the Treatment of Cancer and Diabetes, University of Nebraska at Omaha, March 11, 2002.
  77. Functional and Biospecific Polymers for Therapeutic Gene Delivery at AAPS Workshop on Critical Issues in the Design & Applications of Polymeric Biomaterials in Drug Delivery, Arlington , VA. (February 28 ~ March 1, 2002).
  78. Nonviral Gene Delivery, St. Jude’s Children’s Hospital, Memphis, November, 2001.
  79. Introduction to Gene Therapy at Sunrise School of Pharmacy Session at the AAPS Annual Meeting (Indianapolis), 2000.
  80. Tailor made polymeric gene carriers at the 3rd Congress of Eur Assoc Clin Pharmacol Ther (EACPT), Jerusalem, Israel (3-8, Oct' 99).

Abstracts and Presentations (*speaker)

  1. Mundra V, Pratap A, Singh S and Mahato RI (2011) Vismodegib, a small-molecule inhibitor of Hedgehog (Hh) pathway can prevent liver fibrosis in a rat model. AAPS Annual Meeting (Washington, DC).
  2. Danquah M, Li F, Duke III CB, Miller DD and Mahato RI (2011) Lactic acid and carbonate-based nanotherapies for treating chemoresistant tumors. AAPS Annual Meeting (Washington, DC).
  3. Danquah M, Fujiwara T and Mahato RI (2011) Crosslinked Micellar Drug Delivery for Prostate Cancer. PharmForum (Memphis, TN, 2011)
  4. Li F, Danquah M and Mahato RI (2011) Paclitaxel and Lapatinib loaded Lipopolymer Micelles for Treating Refractory Prostate Cancer. PharmForum (Memphis, TN, 2011)
  5. Li F, Danquah M and Mahato RI (2011) Micelles-based Combination Therapy for Treating Refractory Prostate Cancer 15th International Symposium on Recent Advances in Drug Delivery Systems (Salt Lake City, UT, 2011)
  6. Yang N, Panakanti R and Mahato RI (2011) Treatment of Liver Fibrosis by M6P-HPMA-TFO. 15th International Symposium on Recent Advances in Drug Delivery Systems (Salt Lake City, UT, 2011)
  7. Li F, Danquah M and Mahato RI (2010) Amphiphilic lipopolymer micelles for drug delivery. FIP PSWC/AAPS Annual Meeting (New Orleans, LA)
  8. Danquah M, Fujiwara T and Mahato RI (2010) Lactic acid and carbonate-based block copolymers for micellar drug delivery. 37th CRS Annual Meeting, Portland, OR (July 10-14).
  9. Wu H, Yoon A-R, Yun C-O and Mahato RI (2010) Bipartite adenoviral vector encoding hHGF and hXIAP for improved human islet transplantation. 13th Annual Meeting of the American Society of Gene and Cell Therapy, Washington, DC (May 17-22, 2010).
  10. Yang Y and Mahato RI (2010) Hepatic stellate cell-specific TGF- 1 Gene Silencing for treating Liver Fibrosis. 13th Annual Meeting of the American Society of Gene and Cell Therapy, Washington, DC (May 17-22, 2010).
  11. *Mahato RI, Danquah M, Li F, Fujiwara T, Lu Y and Miller DD (2010) Polymeric Nanomedicines and Combination Therapy for the Treatment of Advanced Prostate Cancer. Biomedical Polymers for Drug Delivery 2010: In Honor of Prof Jindrich Kopecek’s 70th Birthday, March 26-27, 2010.
  12. *Mahato RI (2009) Polymeric Nanomedicines and Combination Therapy for treating Resistant Prostate Cancer, Institute for Inovative NanoBio Drug Discovery and Development, Kyoto University, Japan, December 5, 2009.
  13. *Panakanti R and Mahato RI (2009) E1, E3 and E4 deleted Bipartite Adenoviral vector encoding hVEGF and hIL-1Ra for decreased immunogenicity and improved islet function. AAPS Annual Meeting (Los Angeles, CA, 2009). Received AAPS travel award.
  14. Li F, Lu Y, Miller DD and Mahato RI (2009) Galactose-conjugated Polymeric Micelles for Targeted Drug Delivery. AAPS Annual Meeting (Los Angeles, CA, 2009).
  15. *Zhu L, Lu Y, Miller DD and Mahato RI (2009) Pyridinium cationic lipid-based gene and siRNA delivery. AAPS Annual Meeting (Los Angeles, CA, 2009). Received AAPS travel award.
  16. Wu H and Mahato RI (2009) Reversal of Cytokine-induced Pancreatic Beta Cell Death after XIAP Gene Expression. AAPS Annual Meeting (Los Angeles, CA, 2009).
  17. Mahato RI, Panakanti R, Li F and Cheng G (2009) Gene Delivery and Silencing for Improved Islet Transplantation, 14th International Symposium on Recent Advances in Drug Delivery Systems, in Salt Lake City, UT, February 15-18, 2009.
  18. Panakanti R, Cheng G and Mahato RI, (2009) Construction of bicistronic adenoviral vector encoding genes hHGF and hIL-1Ra for islet transplantation. AAPS Annual Meeting (Atlanta, GA, 2008).
  19. Li F, Cheng G and Mahato RI (2008) MicroRNA-Based shRNA for iNOS Gene Silencing. AAPS Annual Meeting (Atlanta, GA, 2008).
  20. Zhu L, Lu Y1, Miller DD and Mahato RI (2008) Enhancing Gene Delivery Using Pyridinium Cationic Lipids. AAPS Annual Meeting (Atlanta, GA, 2008).
  21. Yang N, Ye Z and Mahato RI (2008) Delivery of TFO Using HPMA Polymer for Liver Fibrosis Treatment. 35th Proc. Int. Symp. Control Rel. Bioact. Mater, New York, NY (July 2008).
  22. Li F, Lu Y, Miller DD and Mahato RI (2008) Galactose-conjugated Polymeric Micelles for Targeted Drug Delivery. 35th Proc. Int. Symp. Control Rel. Bioact. Mater, New York, NY (July 2008).
  23. Panakanti R, Cheng G and Mahato RI (2008) Bicistronic Adenoviral vector encoding hVEGF and hIL-1Ra for improving islet Transplantation. 11th Annual Meeting of the American Society of Gene Therapy, Boston, MA (May 28-June 1, 2008).
  24. Cheng G and Mahato RI (2008) MicroRNA-based Small Interfering RNA Silencing for Inhibiting Apoptosis. 11th Annual Meeting of the American Society of Gene Therapy, Boston, MA (May 28-June 1, 2008).
  25. Zhu L, Lu Y, Miller DD and Mahato RI (2007) Synthesis and Characterization of Pyridinium-based Cationic Lipids for Gene and siRNA Delivery. AAPS Annual Meeting (San Diego, CA, 2007).
  26. Ye Z, Guntaka RV and Mahato RI (2007) Quantification of Sequence-specific Triple Helix Formation. AAPS Annual Meeting (San Diego, CA, 2007).
  27. Zhu L, Ye Z, Cheng K, Miller DD and Mahato RI (2007) Site-specific Delivery of Oligonucleotides to Hepatocytes. 34th Proc. Int. Symp. Control Rel. Bioact. Mater, Long Beach, CA (July 2007).
  28. Li F, Panakanti R and Mahato RI (2007) Gene Expression and Silencing for Successful Islet Transplantation. 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA (May-June 2007).
  29. Chen Y , Ye Z and Mahato RI (2007) siRNA Pool Targeting Different Sites of Human Hepatitis B Surface Antigen Efficiently Inhibits HBV Infection, 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA (May-June 2007).
  30. Ye Z, Guntaka RV and Mahato RI (2007) Sequence-specific Triple Helix Formation with Genomic DNA, 10th Annual Meeting of the American Society of Gene Therapy, Seattle, WA (May-June 2007).
  31. Zhu L, Lu Y, Miller DD and Mahato RI (2007) Synthesis and Characterization of Pyridinium Cationic Lipids for Nucleic Acid Delivery. AAPS PharmForum (Memphis, TN, 2007).
  32. Zhu L, Lu Y, Miller DD and Mahato RI (2007) Synthesis and Characterization of Pyridinium Cationic Lipids for Nucleic Acid Delivery. AAPS PharmForum (Memphis, TN, 2007).
  33. Cheng K and Mahato RI (2007) TGF-ß1 Gene Silencing for Treating Liver Fibrosis. AAPS PharmForum (Memphis, TN, 2007).
  34. *Cheng K and Mahato RI (2007) TGF-ß1 Gene Silencing for Treating Liver Fibrosis. AAPS PharmForum (Memphis, TN, 2007).
  35. *Mahato RI, Cheng K, Ye Z, Chen Yong and Zhu L (2007) Site-specific Delivery and Targeting of Oligonucleotides and siRNA for Treating Hepatitis and Liver Fibrosis, 5th Annual Drug Discovery Conference and Expo (Shanghai, China, May , 2007).
  36. *Mahato RI, De Paula D, Jia X, Cheng K and Narang AS (2007) Gene expression and silencing for improved islet transplantation. Pharmaceutical Science World Congress (Amsterdam, The Netherlands, April 2007).
  37. Jia X, Cheng K and Mahato RI (2006) Construction of Bicistronic Plasmid Encoding Human Vascular Endothelial Growth Factor (hVEGF) and Interleukin-1 Receptor Antagonist (hIL-1Ra) for Improving Human Islet Transplantation. AAPS Annual Meeting (San Antonio, TX, 2006).
  38. Cheng K, Miller DD and Mahato RI (2006) Application of TGF-ß1 Specific siRNA for the Treatment of Liver Fibrosis. AAPS Annual Meeting (San Antonio, TX, 2006).
  39. Cheng K, Guntaka RV and *Mahato RI (2006) Conjugation with Cholesterol Enhances Hepatic Uptake and Bioactivity of Triplex Forming Oligonucleotides. 33rd Proc. Int. Symp. Control Rel. Bioact. Mater (Vienna, Austria).
  40. Ye Z, Guntaka RV and Mahato RI (2006) M6P-BSA-TFO for Treating Liver Fibrosis, National Biotechnology Conference (Boston, June 2006).
  41. Ye Z, Cheng K, Guntaka RV and Mahato RI (2005) Hepatic uptake and subcellular distribution of a triplex forming oligonucleotide-bovine serum albumin conjugate in rats. AAPS Annual Meeting (Nashville, TN, 2005).
  42. Cheng K, Ye Z, Guntaka RV and Mahato RI (2005) Hepatic uptake and subcellular distribution of a triplex forming oligonucleotide in rats. AAPS Annual Meeting (Nashville, TN, 2005).
  43. Narang A, Sabek O, Gaber A and Mahato RI (2005) Effect of interleukin-1 receptor antagonist and vascular endothelial growth factor gene expression on human islet graft survival and function. AAPS Annual Meeting (Nashville, TN, 2005).
  44. Narang A, Thoma L, Miller DD, Rao RK and Mahato RI (2005) Permeation of lipid-insulin conjugate across rat jejunum and Caco2 cell monolayer. AAPS Annual Meeting (Nashville, TN, 2005).
  45. Narang A and Mahato RI (2005) Comparative efficacy of interleukin-1 receptor antagonist and small interfering RNA mediated silencing of inducible nitric oxide synthase in rat pancreatic islets. AAPS Annual Meeting (Nashville, TN, 2005).
  46. *Ye Z, Cheng K, Guntaka RV and Mahato RI (2005) Site-Specific Delivery of Triplex Forming Oligonucleotides to Hepatic Stellate Cells. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).
  47. *Narang AS, Fraga D, Gaber AO and Mahato RI (2005) Adenoviral Delivery of Interleukin-1 Receptor Antagonist Gene to Human Pancreatic Islets. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).
  48. Narang AS, Seth P, Rao RK, Miller DD and Mahato RI (2005) Transepithelial Permeation of Insulin and Insulin Derivatives. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).
  49. Cheng K, Ye Z, Guntaka RV and Mahato RI (2005) Biodistribution of Triplex Forming Oligonucleotides Against Typea1(I) Collagen Gene Promoter in Normal and Fibrotic Rats. 32nd Proc. Int. Symp. Control Rel. Bioact. Mater (Miami, FL, 2005).
  50. Ye Z, Guntaka RV and Mahato RI (2004) Targeting Triplex Forming Oligonucleotide to Hepatic Stellate Cells 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).
  51. Narang AS, Thoma L, Miller DD and Mahato RI (2004) Effect of Cationic Lipid Headgroups on Gene Transfer. 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).
  52. *Mahato RI, Cheng K, Fraga D, Gaber AO and Guntaka RV (2004) Adenovirus-Based Vascular Endothelial Growth Factor Gene Delivery to Human Pancreatic Islets. 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).
  53. *Mahato RI and Guntaka RV (2004) Modulation of Gene Expression by RNAi, Antisense and Antigene. 31st Proc. Int. Symp. Control Rel. Bioact. Mater (Hawai, 2004).
  54. Narang AS, Fraga D, Zhang C, Sabek O, Kotb M, A. Gaber AO and Mahato RI (2003) Ex vivo vascular endothelial growth factor gene delivery to human pancreatic islets. AAPS Annual Meeting, Salt Lake City, Utah (October 26-30, 2003).
  55. Cheng K, Fraga D, Guntaka RV, Kotb M, Gaber AO and Mahato RI (2003) Adenovirus-based vascular endothelial growth factor gene delivery to human pancreatic islets. AAPS Annual Meeting, Salt Lake City, Utah (October 26-30, 2003).
  56. *Mahato RI and Guntaka RV (2003) Challenges for Oligonucleotide Delivery. Proc. Int. Symp. Control Rel. Bioact. Mater. 20: (Glasgow, Great Britain).
  57. Narang AS , Cheng K, Henry J, Zhang C, Fraga D, Sabek O, Kotb M, Gaber AO and Mahato RI (2003) Lipid-based gene delivery to human pancreatic islets. Proc. Int. Symp. Control Rel. Bioact. Mater. 20: (Glasgow, Great Britain).
  58. Kumar N, Z Ye, Thoma L, Miller DD and Mahato RI (2003) Design of PEI-based lipopolymeric carriers for gene delivery. Proc. Int. Symp. Control Rel. Bioact. Mater. 20: (Glasgow, Great Britain).
  59. Ye Z, Kumar N, Thoma L, Miller DD and Mahato RI (2003) Hydrophobization of cationic polymers for enhanced gene delivery. 6th Annual Meeting of the American Society of Gene Therapy (Washington, D.C.).
  60. Mahato RI , Wang DA, Narang AS, Kotb M, Gaber AO, Miller DD and Kim SW (2002) Synthesis of T-shaped water soluble lipopolymers for gene delivery. Proc. Int Symp. Control. Rel. Bioact. Mater. 29: (Seoul, Korea).
  61. Mahato RI, Henry J, Narang AS, Mitra S, Fraga D, Sabek O, Kotb M and Gaber AO (2002) Nonviral approaches for growth factor gene delivery to human pancreatic islet. Proc. Int. Symp. Controlled Rel. Bioact Mater. 29; (Seoul, Korea).
  62. Narang AS, J Henry, S Mitra, D Fraga, O Sabek, M Kotb, AO Gaber and RI Mahato (2002) Synthetic Vector for grouwth factor gene delivery to human islets. 5th ASGT Annual Meeting (Boston, MA).
  63. Wang DA, Narang AS, Kotb M, Gaber AO and Mahato RI (2002) T-Shaped water soluble lipopolymers for gene delivery. 5th ASGT Annual Meeting (Boston, MA).
  64. Furgeson DY, Yokman J, Mahato RI and Kim SW (2002) Biodistribution of insoluble lipatticulate-based system. Proc. Int. Symp. Control Rel. Bioact. Mater. 29: (Seoul, Korea).
  65. Han S-O, Lee M, Mahato RI and Kim SW(2001) Water-Soluble Lipopolymer/p2CMVmIL-12 Complex for Cancer Treatment. AAPS Annual Meeting, Denver (October, 2001).
  66. Furgeson DY, Mahato RI and Kim SW (2001) Synthesis and characterization of insoluble lipopolymers for gene delivery. AAPS Annual Meeting, Denver (October, 2001).
  67. Maheshwari A, Mahato RI and Kim SW(2001) Design of novel steroidal peptides for gene delivery. AAPS Annual Meeting, Denver (October, 2001).
  68. Mahato RI, Lee M, Han S-O, Maheshwari A, and Kim SW (2001) Water soluble lipopolymers for interleukin-12 delivery. 28th Int Symp on Control Rel Bioactive Materials, San Diego (June 2001).
  69. *Han S-O, Mahato RI and Kim SW (2001) Water soluble lipopolymer for gene delivery. 4th Annual Meeting of the American Society of Gene Therapy, Seattle (May 30-June 4, 2001) (This abstract was selected as one of the top 3 abstract by the American Society of Gene Therapy and S-O Han was awarded $1000 at the symposium on May 30-June 3, 2001).
  70. Mahato RI, Lee M, S-O Han, Maheshwari A and Kim SW(2001) Water soluble lipopolymer-based interleukin-12 delivery. 10th Int Symp on Recent Advances in Drug Delivery Systems, Salt Lake City (February 2001).
  71. Mahato RI, Maheshwari A, Furgeson DY, Han S-O and Kim SW(2000) Polymeric-gene carriers for cancer treatment. Int Symp Biomat Drug Del Syst, Cheju Island, Korea (20-22, Aug' 00).
  72. Benns JM, Maheshwari A, Furgeson DY, Mahato RI and Kim SW(2000) Folate-PEG-folate-graft-PEI as a gene carrier. Int Symp Biomat Drug Del Syst, Cheju Island, Korea (20-22, Aug' 00).
  73. Mahato RI, A Maheshwari A, McGregor J, Samlowski WE and Kim SW (2000) Polymeric carriers for intratumoral delivery of cytokine genes. 3rd Annual Meeting of American Society of Gene Therapy, Denver (31 May-4 June’00).
  74. *Mahato RI and Kim SW (1999) Tailor made polymeric gene carriers. 3rd Congress of Eur Assoc Clin Pharmacol Ther (EACPT), Jerusalem, Israel (3-8, Oct' 99).
  75. *Mahato RI, Anwer A, Meaney C, Tagliaferri F, Smith LC and Rolland A (1998) Factors influencing cationic lipid-based systemic gene delivery and expression. Proc Int Symp Control Rel Bioact Mater 25: 176-177.
  76. Smith LC, Logan M, Tagliaferri F, Monera O, Mahato RI, Reimer D, Wilson E, Proctor B and Rolland A (1998) Size dependence for dispersion of DNA/cationic lipid complexes in solid tumors. Fourth Cold Spring Harbor Gene Therapy Meeting, Sept'98.
  77. Freimark BD, Bishop JS, Blezinger HP, Deshpande DS, Mahato RI, Florack VJ and Pericle F (1998) In vivo administration of plasmid/cationic lipid complexes induces a cytokine pattern distinct from cationic lipids and plasmids. Fourth Cold Spring Harbor Gene Therapy Meeting, Sept' 98.
  78. *Mahato RI, T Kanamaru T, Takakura Y and Hashida M (1996) Stability and disposition of phosphorothioate oligonucleotides in mice. 116th Annual Meeting of Pharmaceutical Association of Japan, Kanazawa.
  79. *Mahato RI, Takakura Y and Hashida M (1996) Disposition and gene expression of plasmid DNA complexed with cationic carriers. Proc Intl Symp Control Rel Bioact Mater 23: 265-266.
  80. *Mahato RI, Takakura Y and Hashida M (1996) Disposition of antisense oligonucleotides to the hepatocytes using macromolecular carrier systems. Jpn Soc Drug Del Sys, July, Kyoto.
  81. Mahato RI, Yoshida M, Nomura T, Kawabata K, Takakura Y and Hashida M (1995) Physicochemical and disposition characteristics of plasmid DNA complexed with cationic liposomes. Proc Intl Symp Control Rel Bioact Mater 22: 418-419.
  82. Takakura Y, Mahato RI, Kawabata K, Sawai K, Yoshida M and Hashida M (1994) Pharmacokinetics of oligonucleotides disposition in the body. 1st Intl Antisense Conf Jpn, December, Kyoto.
  83. Mahato RI , C Thies C, Lubiniewski A and Ravi VN (1994) Polymer mixture nanoparticles for ocular drug delivery. Invest Ophthalmol Vis Sci 35: 2218.
  84. Lee VHL, LeeYH, Ohdo S, Zhu J and Mahato RI (1994) Dosing time influence on the ocular and systemic absorption on topically applied b-adrenergic antagonists in the pigmented rabbit. Invest. Ophthalmol. Vis. Sci. 35: 1387.
  85. Lee YH, Mahato RI, Chung RYB, and Lee VHL (1993) Corneal and noncorneal absorption of topically applied ?-adrenergic antagonists in the pigmented rabbit. Pharm. Res. 10: S359.
  86. Thies C, Mahato RI and Ravi VN (1993) Ocular drug delivery systems. Association of International Chemical Engineers Meeting.
  87. Mahato RI, Halbert GW, Willmott N and Whateley TL (1992) Preparation of microspheres for intra-articular administration. Proc Int Symp Control Rel Bioact Mater 19: 341-342.
  88. Mahato RI, Halbert GW and Willmott N (1992) Preparation and characterization of microspherical delivery systems. ICI Science Link Meeting, Mereside, England.
  89. Mahato RI, Willmott N and Vezin WR (1991) Preparative techniques for albumin microspheres. Proc Int Symp Control Rel Bioact Mater 18: 375-376.
  90. Mahato RI, Willmott N and Vezin WR (1991) Preparation and characterization of albumin microspheres. British Colloid Science Student Meeting, Nottingham.

Academic Committee Assignments

PhD Committees (Chair)

  1. Virender Kumar (2011-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Design and Synthesis of Polymers for Drug and siRNA Delivery.
  2. Di Wen (2011-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Design and Synthesis of Polymers for Drug and siRNA Delivery for Improved Islet Transplantation.
  3. Vaibhav Mundra (2009-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Combination of Stem Cells and Gene Therapy for Improving Islet Transplantation.
  4. Hao Wu (2008-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Stem Cell and Gene Therapy for Improving Islet Transplantation.
  5. Michael Kofi Danquah (2007-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Polymeric Micelles for Treating Prostate Cancer.
  6. Ningning Yang (2006-2011) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Site-specific Delivery of siRNA and Oligonucleotides for treating Liver Fibrosis. Currently working as an Assistant Professor at Manchester College of Pharmacy, Fort Wayne, IN.
  7. Feng Li (2006-2011) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Growth Factor and Antiapoptotic Gene Delivery to Human Pancreatic Islets for treating Type I Diabetes. Currently working as an Assistant Professor at Hampton University, Hampton, VA.
  8. Lin Zhu (2005-2010) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Site-specific Delivery of Nucleic Acids. Currently working as a postdoctoral fellow at Northeastern University, Boston, MA.
  9. Ravikiran Panakanti (2005-2010) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Viral and Non-viral Gene Therapy for Improving Islet Transplantation. Currently working as an Assistant Professor at Roosevelt University, Chicago, IL.
  10. Zhaoyang Ye (2002-2007). Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Triplex Forming Oligonucleotide Delivery to Hepatic Stellate Cells. He worked as a Postdoctral Fellow in the Department of Biomedical Engineering, John Hopkins University, Baltimore, MD from 2007-2009. He is currently working an Associate Professor, The State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, 130 Meilong Road, P.O.Box 309 Shanghai, P.R. China 200237.
  11. Kun Cheng (2002-2007). Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Adenoviral Gene Delivery to Human Islets & Biodistribution and Delivery Systems of Triplex Forming Oligonucleotides for treatment of Liver Fibrosis. Currently working as an Assistant Professor, Department of Pharmaceutical Sciences, University of Missouri Kansas City, MO.
  12. Ajit S. Narang (2001-2006). Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Nonviral and Adenoviral Gene Delivery to Human and Rat Islets. Synthesis of Novel Cationic Lipids for Gene Delivery. Currently working at Bristol Myers Squibs, Inc.

PhD Committee Member

  1. Wararat Limothia (2008-Present) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Population Pharmacokinetics
  2. Chikezie O. Madu (2007-Present) Department of Pathology and Laboratory Medicines, University of Tennessee Health Science Center. Cancer Gene and Drug Therapy
  3. Krishna Bhandari (2007-2008) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Site-specific Delivery of miRNA for treating Hepatocellular Carcinoma
  4. Vinayagam Kannan (2006-2010) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Development and Evaluation of Paclitaxel-Loaded Liposomal Formulations for Targeted Drug Delivery to Breast Cancer. Currently working as a scientist at Akorn, Inc
  5. Hari Desu (2005-2009) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Targeted Delivery of Surface Modified Nanoparticles: Modulation of Inflammation for Acute Lung Injury. Currently working at Innovarpharma, LLC.
  6. Murali K. Divi (2004-2007) Department of Pharmaceutical Sciences, University of Tennessee Health Science Center. Targeted Drug Delivery to Glioma Brain Tumors.
  7. Chad Batson (2003-2005). Department of Molecular Sciences, University ot Tennessee Health Science Center.
  8. Darin Y. Furgeson (2000-2003). Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah. Structural and Functional Effects of Polyethylenimine Gene Carriers. Currently working as an Assistant Professor, Department of Pharmaceutical Sciences, University of Wisconsin, Madison, WI
  9. Jonathan M. Benns (1998 - 2001). Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah. Polymeric Gene Carriers. Currently studying law at the University of Utah, Salt Lake City.

Advisor for Summer Students and Exchange Students

  1. Jade M. Readus (June-August 2010) Second year undergraduate student from Tennessee State University, Nashville in my laboratory as a summer student to work on the Interaction of Hedgehog Pathway and MAP-Kinases in Hepatic Stellate Cells.
  2. Hashani Perkins (June-August 2010) First year medical student from UTHSC worked in my laboratory as a summer student to work on gene delivery to pancreatic β-cells.
  3. Daniel de Paula (Feb-August 2006) Visiting graduate student from the Faculty of Pharmaceutical Sciences of Ribeiräo Preto at the University of Säo Paulo in Brazil. Working in my laboratory as a Research Scholar to conduct research on Protein and siRNA Delivery. Currently an Assistant Professor at Universidade Estadual do Centro-Oeste - UNICENTRO, PR, Brazil.
  4. Houssam Hajj Houssein (June-July, 2006), B.S. student from Delta State University, Cleveland, Mississippi on a project entitled, "Site-specific Delivery of TFO for Treating Liver Fibrosis (100% responsibility).
  5. Brandon Kyle Slaughter (June-July, 2005), B.S. (Biology) student from the University of Memphis on a project entitled "Genetic Modifications for Improved Islet Transplantation" (100% responsibility).
  6. Margaret M Thomson (June 25~July 18, 2003) PharmD/PhD student, Department of Pharmaceutical Science, University of Tennessee on a project entitled, “Design and synthesis of cationic lipid and liposome preparation for gene delivery (100% responsibility).
  7. Altovise Ewing (June-July2003), B.S. student from Rhodes College, Memphis on a project entitled "Adenovirus-Based hVEGF Gene Delivery to Human Islets” (100% responsibility).
  8. Deependra Mahato (January-July2002), B.S. student from Rhodes College, Memphis on a project entitled "Polymeric Carriers for Gene Delivery”(100% responsibility).

Post-doctoral Fellows and Technicians (Role: Supervisor)

  1. Saurabh Singh (2011-Present), Ph.D. Following his PhD training in degree in Biochemistry from Aligarh Muslim University, India. He has previously worked at the University of Louisville as a post-doctoral fellow and has experience in molecular toxicology, cell signaling and stem cell biology. He is currently a postdoctoral fellowship at UTHSC, Memphis.
  2. Wenli Lu (2009-2010), Ph.D. Following her PhD training in Pharmaceutics and Drug Delivery at China Pharmaceutical University, she joined the same university as an Assistant Professor in 2006. She is working on genetic modification of human islets for improved islet transplantation. She is currently Postdoctoral fellowship at UTHSC, Memphis.
  3. Guofeng Cheng (2007-2009), Ph.D. Following his PhD training in Molecular Biology from Chinese Academy of Agricultural Sciences, he joined the University of Colorado for a postdoctoral fellowship. He worked on Genetic Modification of Human Islets for Improved Islet Transplantation and construction of adenoviral vectors. Currently, he is working as a Professor at Shanghai Research Center for Animal Biotechnology, Shanghai, China.
  4. Rubi Mahato (2006-2008) Following her B.Pharm. from India, she joined our laboratory to work as a visiting research assistant on gene delivery to islets. She is currently a graduate student at the University of Missouri Kansas City, MO.
  5. Yong Chen (2006-2007) M.S., M.D., Associate Professor at the Hepatology Institute of Huaian 4th People’s Hospital, Huaian, Jiangxu, P.R. China. He is currently working on siRNA Delivery for Treating Hepatitis B.
  6. Xiangxu Jia (2005-2006), B.S. degree in Immunology from Chongqing Third Medical Univeristy in 1992. Following that, she obtained a M.S. degree in Immunology from Shanghai Second Medical University, in 2003. She worked on Genetic Modifications of Human Islets for Improved Transplantation. Currently she is working at Vanderbilt University, Nashville.
  7. Neeraj Kumar (2002-2003), Ph.D. in Organic Chemistry of Indian Institutes of Technology, Roorkee, India on Synthesis and Characterization of Water Soluble Lipopolymer. Currently working as an Assistant Professor, Department of Pharmaceutical Sciences, National Institute of Pharmaceutical Education & Research, SAA Nagar, Mohali 160-062, India.
  8. Dong-an Wang (2001-2002), Ph.D. in Polymer Science from Zhejiang University, China on Synthesis and Characterization of Water Soluble Lipopolymer. Currently working as an Assistant Professor, Division of Bioengineering, Nanyang Technological University, Singapore.
  9. Suchareeta Mitra (2001-2002), Ph.D. in Biochemistry/Zoology from Delhi University on Gene Delivery to Human Islets. Currently working as a postdoctoral fellow at the Department of Molecular Sciences, University of Tennessee Health Science Center, Memphis.

School/College Committee Assignments

  • Member, Graduate Curriculum Committee (2003-present), University of Tennessee Health Science Center, Memphis, TN.
  • Member, College of Pharmacy Curriculum Committee (2005-Present), University of Tennessee Health Science Center, Memphis, TN.
  • Member, Faculty Development Committees (2002-Present), University of Tennessee Health Science Center, Memphis, TN.